Cancer: Drugs:Written question - HL3340

Q
Asked by Lord Avebury
Asked on: 05 November 2015
Department of Health
Cancer: Drugs
Lords
To ask Her Majesty’s Government which drugs have been delisted from the Cancer Drugs Fund; how many patients are currently being treated with each drug; and what steps they are taking to develop a new system for prescribing each drug.
A
Answered by: Lord Prior of Brampton
Answered on: 19 November 2015

Details of the drugs removed from the national Cancer Drugs Fund (CDF) list following re-prioritisation are shown in tables 1 and 2. The latest version of the list is available on NHS England’s website at: www.england.nhs.uk/ourwork/pe/cdf/. A copy is attached.


Table 1: Confirmation of previously notified drugs and indications delisted on 12 March 2015

Drug

Indication removed

Aflibercept

2nd line in combination with irinotecan-based combination chemotherapy for metastatic colorectal cancer

Bendamustine

Treatment of patients with indolent non-Hodgkin’s lymphoma who are refractory to rituximab

Bevacizumab

1st line in combination with oxaliplatin–based combination chemotherapy for metastatic colorectal cancer

Bevacizumab

1st line in combination with irinotecan–based combination chemotherapy for metastatic colorectal cancer

Bevacizumab

1st line in combination with single agent fluoropyrimidine–based chemotherapy for metastatic colorectal cancer.

Bevacizumab

In combination with carboplatin and gemcitabine chemotherapy for recurrent platinum sensitive ovarian cancer

Bortezomib

Re-treatment in patients with relapsed myeloma

Bortezomib

Treatment of patients with relapsed Waldenstrom’s macroglobulinaemia

Bortezomib

Treatment of patients with relapsed mantle cell lymphoma

Bosutinib

Treatment of blast phase chronic myeloid leukaemia

Cetuximab

2nd line in combination with irinotecan chemotherapy for metastatic colorectal cancer in patients with RAS wild type (non-mutated) tumours

Dasatinib

Treatment of the lymphoid blast phase of chronic myeloid leukaemia

Everolimus

Treatment of progressive unresectable or metastatic well differentiated neuroendocrine tumour of the pancreas

Lapatinib

In combination with capecitabine chemotherapy for HER-2 receptor positive locally advanced or metastatic breast cancer

Ofatumumab

Treatment of relapsed or refractory chronic lymphatic leukaemia

Pazopanib

Treatment of previously treated metastatic non-adipocytic soft tissue sarcomas

Pegylated liposomal doxorubicin

1st or 2nd line chemotherapy of angiosarcoma

Pegylated liposomal doxorubicin

Chemotherapy of primary malignant sarcomas of the heart and great vessels

Source: National Cancer Drugs Fund List Ver 6.0


Table 2: Confirmation of previously notified drugs and indications delisted on 4 November 2015

Drug

Indication removed

Albumin bound Paclitaxel

First line treatment of advanced adenocarcinoma of the pancreas in combination with Gemcitabine

Bendamustine

2nd or subsequent line treatment of chronic lymphatic leukaemia for patients whom fludarabine combination therapy is not a therapeutic option

Bendamustine

2nd and subsequent line of treatment of mantle cell lymphoma in patients who have not received previous Bendamustine

Bevacizumab

Treatment of patients with triple negative metastatic breast cancer and/or prior Taxane therapy

Bevacizumab

2nd or 3rd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received Bevacizumab

Bosutinib

Treatment of chronic phase CML refractory to Nilotinib or Dasatinib

Bosutinib

Treatment of accelerated phase CML refractory to Nilotinib or Dasatinib

Bosutinib

Treatment of accelerated phase CML where there is significant intolerance to Dasatinib and Nilotinib.

Cetuximab

3rd and subsequent line treatment of metastatic colorectal cancer as a single agent

Cetuximab

3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176

Dasatinib

Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy including Imatinib

Everolimus

2nd or 3rd line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy

Lenalidomide

2nd line treatment of multiple myeloma in patients who have contraindications to the use of Bortezomib

Panitumumab

3rd and subsequent line treatment of metastatic colorectal cancer as a single agent

Panitumumab

3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176

Pegylated Liposomal Doxorubicin

2nd line treatment of Fibromatosis

Peptide Receptor Radionucleotide Therapy (Lutetium177 Octreotate or Yttrium90 Octreotide/Octreotate)

Treatment of advanced neuro-endocrine tumours i.e. for pNETS after Sunitinib/chemotherapy, for mid-gut carcinoid, after octreotide/somatostatin therapies.

Pomalidomide

Treatment of relapsed and refractory multiple myeloma in patients who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Source: National Cancer Drugs Fund List Ver 6.0


NHS England publishes information on the number of patient applications for particular drugs/indications contained on the national CDF list on a quarterly basis. This information also includes the number of applications approved through the individual CDF request process. The latest information isattached as it is too long to be included in this answer. It is also available at:

www.england.nhs.uk/ourwork/pe/cdf/ and a copy of this is also attached.


The Government is committed to the CDF and is working with NHS England and the National Institute for Health and Care Excellence on the future arrangements for the Fund.

Cancer Drugs Fund List (PDF Document, 361.03 KB)
CDF Reporting template (Excel SpreadSheet, 184.54 KB)
Patient Numbers (Word Document, 51.12 KB)

Share this page